The Addictions and Their Treatment Course

We will be coming together virtually in 2021!

The live webinar Q&A session for this virtual course will be held on Friday, October 1, 2021 and Saturday, October 2, 2021.

Register Now

Note: You can find previously recorded courses on the Educational Opportunities page.

Who Should Attend?

The field of Addiction changes frequently as new information becomes available. This course presents a broad-based overview of addictions and up-to-date information in the field of addiction. It is recommended for physicians, PA-Cs, nurse practitioners, and other professionals who wish to stay updated on the most recent trends in the addiction field. It is equally relevant to junior faculty and clinicians as well as experienced practitioners and is intended to help psychiatrists prepare for ABPN certification and recertification examinations in Addiction Psychiatry.

View Continuing Education Credits

View the 2021 Addictions and Their Treatment Disclosure to Learners Statement

Educational Objectives

At the conclusion of this activity, participants should be able to:

  1. Describe new advances in the pharmacotherapy and psychotherapy of addictive disorders.
  2. Discuss the epidemiology of substance use disorders and their co-occurrence with other psychiatric disorders and review current recommended approaches for concurrent treatment of substance use disorders and other mental health disorders.
  3. Describe the role of genetics in the risk for developing alcohol and other drug use disorders.
  4. Identify the major neurobiological pathways involved in addictive disorders.
  5. Identify the molecular mechanisms that are altered following drug and alcohol use.
  6. Review the literature on screening and brief intervention effectiveness and teach this technique so it is applied.
  7. Review current treatment guidelines and how to utilize them in clinical practice.
  8. Describe special considerations for addiction diagnosis and treatment for women, underrepresented racial and ethnic minorities, youth, older adults, hospitalized patients, and patients with comorbid health conditions.
Topics

Alcohol
Behavioral Addictions
Benzodiazepines: The Hidden Epidemic
Cannabis
Co-Morbidity of Substance and other Psychiatric Disorders
Emerging Drugs
Forensic Issues in Addiction
General Concepts and Epidemiology
Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
Medical Comorbidities in Patients with Substance Use Disorders
Motivational Interviewing
Naloxone Overdose Training
Neurobiology and Genetics
Pain and Addiction
Pregnancy and Substance Use Disorders
Psychosocial Treatments of the Addictions
Review of Opioids and Treatment of Opioid Use Disorders
Sex and Drugs: Gender Differences in Substance Use Disorders
Stimulant-Related Disorders
Substance Use Disorders In the Older Population
Substance Use Disorder Treatment in Hospital Settings
Suicide and Substance Use Disorders
Tobacco
Urine Drug Testing
Youth with Substance Use Disorders and ADHD

Schedule
Friday, October 1, 2021
*All times shown are Eastern Daylight Time.
12:30 PM Welcome and Introduction to the Live Session
12:35 PM – 2:15 PM Kevin A. Sevarino MD, PhD

  • General Concepts and Epidemiology
  • Neurobiology and Genetics
  • Urine Drug Testing

Carla Marienfeld, MD

  • Motivational Interviewing

Ayana Jordan, MD

  • Inequities in Addiction Treatment for Racial and Ethnic Minority Populations
2:15 PM – 2:30 PM Break
2:30 PM – 3:50 PM Edward V. Nunes, MD

  • Co-Morbidity of Substance and other Psychiatric Disorders
  • Psychosocial Treatment of the Addictions

Smita Das, MD, PhD, MPH

  • Tobacco

Bryon Adinoff, MD

  • Alcohol
3:50 PM – 4:05 PM Break
4:05 PM – 5:25 PM Steven L. Batki, MD

  • Stimulant-Related Disorders
  • Medical Comorbidities in Patients with Substance Use Disorders

Sanchit Maruti, MD

  • Substance Use Disorder in Hospital Settings

Roger Chou, MD

  • Pain and Addiction
5:25 PM – 5:30 PM End of Day Wrap Up
Saturday, October 2, 2021
11:00 AM Welcome and Introduction to the Live Session
11:05 AM – 12:25 PM Michelle Lofwall, MD

  • Pregnancy and Substance Use Disorders
  • Naloxone Overdose Training

John A. Renner, Jr., MD

  • Review of Opioids and Treatment of Opioid Use Disorders

Kathleen T. Brady MD, PhD

  • Sex and Drugs: Gender Differences in Substance Use Disorders
12:25 PM – 12:40 PM Break
12:40 PM – 2:00 PM Richard K. Ries, MD

  • Suicide and Substance Use Disorders
  • Benzodiazepines: The Hidden Epidemic

Stephanie Hrisko, MD and Panel

  • Substance Use Disorders in the Older Population

Amy M. Yule, MD

  • Youth with Substance Use Disorders and Attention Deficit Hyperactivity Disorder
2:00 PM – 2:15 PM Break
2:15 PM – 3:35 PM Petros Levounis, MD, MA

  • Cannabis
  • Emerging Drugs

Laurence M. Westreich, MD

  • Forensic Issues in Addiction

Timothy W. Fong, MD

  • Behavioral Addictions
3:35 PM – 3:40 PM End of Day Wrap Up

Presenters

Bryon Adinoff, MD

Bryon Adinoff, MDBryon Adinoff, MD is an addiction psychiatrist and academician. Dr. Adinoff is presently a Clinical Professor at the University of Colorado School of Medicine. He retired in 2018 as the Distinguished Professor of Alcohol and Drug Abuse Research in the Department of Psychiatry at the University of Texas Southwestern Medical Center and as a psychiatrist for 30 years with the Department of Veterans Affairs, where he served as the director of substance use disorder treatment programs at both the Charleston, SC and Dallas, TX VA Medical Centers. Dr. Adinoff obtained his medical training at Michigan State University, completed his residency in psychiatry at Tulane University, and obtained a fellowship in the Laboratory of Clinical Studies at the National Institutes on Alcohol Abuse and Alcoholism at the NIH. Dr. Adinoff’s laboratory focused on using a variety of pharmacologic, cognitive, and behavioral probes to explore the neural and endocrine disruptions that occur in cocaine and alcohol use disorders and, more recently, compulsive tanning. Dr. Adinoff has published more than 200 articles, reviews, and book chapters on the biology and treatment of addiction, and he is the Editor-in-Chief of The American Journal of Drug and Alcohol Abuse. Dr. Adinoff research has been funded by the the National Institutes on Drug Abuse (NIDA), Alcohol Abuse and Alcoholism (NIAAA) and Department of Veterans Affairs. He has been recognized as a Distinguished Fellow by the American Academy of Addiction Psychiatry and the American Psychiatric Association and is a Fellow in the American College of Neuropsychopharmacology. In his semi-retired status, he is becoming increasingly involved in advancing drug policy reform. In this capacity, he is Executive Vice President of Doctors for Cannabis Regulation, on the advisory board of SPORE (Society for Psychedelic Outreach, Reform and Education), and on the Drug Policy Alliance’s Marijuana Justice Coalition.

Steven L. Batki, MD

Steven L. Batki, MDDr. Batki is Professor, Department of Psychiatry and Behavioral Sciences at the Weill Institute for Neurosciences at the University of California, San Francisco (UCSF) School of Medicine and Chief of the AddictionRecovery Treatment Services (ARTS) at the San Francisco Veterans Affairs Health Care System (SFVAHCS).

Dr. Batki directs the UCSF/SFVAHCS Addiction Research Program and is senior consultant to the UCSF/SFVAHCS Addiction Psychiatry Fellowship Program.Previously, he served as Director of the Division of Substance Abuse and Addiction Medicine at San Francisco General Hospital.

Dr. Batki works in addiction research, training, and clinical services. His research focuses on the pharmacological and neurobehavioral treatment of addiction and co-occurring psychiatric and medical disorders in Veterans. He has conducted VA, DoD, NIDA, and NIAAA-fundedresearchaimedto improve the treatment of cocaine, and methamphetamine use disorders as well as alcohol and opioid use disorders. Much of his work has focused on Veterans and other patients with co-occurring medical disorders such as HIV, Hepatitis C, and TB, and co-occurring psychiatric disorders including PTSD, serious mental illness, and the effects of traumatic brain injury (TBI).

Kathleen T. Brady, MD, PhD

Kathleen T. Brady, MD, PhDDr. Brady is an experienced clinical and translational researcher and has been conducting scientific investigations and clinical work in the field of addictions and psychiatric disorders for over 30 years. Her research focuses on pharmacotherapy of substance use disorders, comorbidity of psychiatric disorders and addictions (e.g., posttraumatic stress disorder and bipolar disorder), gender differences and women’s issues in addictions, and the neurobiologic connections between stress and addictions. She has received numerous federal research grants and has published over 300 peer-reviewed journal articles and co-edited 10 books. She is the Vice President for Research at the Medical University of South Carolina. She is the principal Investigator of MUSC’s Clinical and Translational Science Award (CTSA), Principal Investigator of the Southern Consortium Node of the NIDA-funded Clinical Trials Network and Director of MUSC’s Women’s Research Center. Her dedication to furthering research careers has attracted a number of junior investigators and clinicians. She has served at the President of the Association for Medical Education and Research in Substance Use Disorders (AMERSA), the American Academy of Addiction Psychiatry (AAAP) and is currently the President of the International Society of Addiction Medicine (ISAM).

Roger Chou, MD, FACP

Roger Chou, MD, FACPRoger Chou is a Professor in the Departments of Medicine, and Medical Informatics & Clinical Epidemiology at Oregon Health & Science University (OHSU) School of Medicine, and Staff Physician in the Internal Medicine Clinic at OHSU. He has served as Director of the Pacific Northwest Evidence-based Practice Center since 2012. He has authored over 250 peer-review articles, including numerous systematic reviews, and led or participated in clinical guideline development efforts in chronic pain and opioids, addiction, and other topics. His reviews have been used by the American College of Physicians, the Centers for Disease Control and Prevention, the US Preventive Services Task Force, the American Pain Society, and others to develop clinical practice guidelines. As Director of Clinical Guidelines Development for the American Pain Society, he led the development of clinical practice guidelines on methadone safety, use of opioids for chronic pain, and evaluation and management of low back pain. He led a systematic review on benefits and harms of long-term use of opioids that was used to develop the 2016 CDC guideline on use of opioids for chronic pain, for which he served on the steering committee, and led reviews on methadone policy, models of care for medications for treatment of opioid use disorder and use of naloxone to reverse opioid overdose. Dr. Chou serves as a methodologist for several World Health Organization guideline development groups, served as Coordinating Editor of the Cochrane Back and Neck Group, is Senior Editor of the Cochrane Musculoskeletal Group, and serves on the Board of Scientific Counselors of the CDC’s National Center for Injury Prevention and Control.

Smita Das, MD, PhD, MPH

Smita Das, MD, PhD, MPHSmita Das, MD, PhD, MPH is Board Certified in Psychiatry, Addiction Psychiatry and Addiction Medicine. Dr. Das studied Chemistry and Statistics at Stanford, completed her Masters in Public Health at Dartmouth College, and then completed her MD/PhD in Community Health at the University of Illinois at Urbana Champaign. She completed psychiatry residency and was chief resident at Stanford followed by an addiction psychiatry fellowship at UCSF. She has over 2 decades of experience in research in healthcare quality and addiction. Dr. Das has an appointment to the APA Addiction Council. She has been President of the Northern California Psychiatric Society, an APA District Branch. Prior to her position as Medical Director of Psychiatry at Lyra Health, Dr. Das was Director of Addiction Treatment Services at the Palo Alto VA. In addition to her work at Lyra, Dr. Das practices in the Dual Diagnosis Clinic at Stanford School of Medicine where she is a Clinical Associate Professor.

Timothy W. Fong MD

Timothy W. Fong MDDr. Fong is a Professor of Addiction Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA.

He is the director of the UCLA Addiction Psychiatry Fellowship, a one-year program that provides clinical training in the management of addictive disorders.

He is also the co-director of the UCLA Gambling Studies Program. The purpose of this program is to examine the underlying causes and clinical characteristics of gambling disorder in order to develop effective, evidence-based treatment strategies.

Dr. Fong is Director of the Steering Committee to the UCLA Cannabis Research Initiative, a multidisciplinary effort to examine the full impact of cannabis on the body, mind and brain.

Finally, he is the Director of the UCLA Sports Psychiatry Service, a multidisciplinary treatment program that manages the psychiatric needs of UCLA student athletes and professional athletes.

Scope of Work

  • Creating and delivering continuing education programs for sober and mental health companions
  • Determining best practices for sober and mental health companions
Ayana Jordan, MD, PhD

Ayana Jordan, MD, PhDAyana Jordan, MD, PhD, an Addiction Psychiatrist, Assistant Professor of Psychiatry in the Department of Psychiatry, and Director of the Social Justice and Health Equity Curriculum, is dedicated to creating spaces and opportunities for more people of color, specifically Black women in academia who are vastly underrepresented. The fundamental message of equity and inclusion has informed her research, clinical work and leadership duties at Yale and beyond. Dr. Jordan is also one of the new Associate Program Directors for the Yale Psychiatry Residency, a large group of 64 physicians providing mental health and addiction services throughout Yale medical systems in the state of CT.

She recently became Director of Equity, Diversity and Inclusion for the Justice Community Opioid Innovation Network within the National Institute of Drug (Ab)use, where she’ll be working to improve health outcomes for people with opioid use disorder in the carceral system. Dr. Jordan also serves the medical director of Recognizing and Eliminating disparities in Culturally-informed Healthcare or (REACH), a Substance (Ab)use and Mental Health Services Administration grant, in conjunction with the American Academy of Addiction Psychiatry, geared at increasing the number of addiction specialists from racial and ethnic minority populations who obtain training to provide culturally-informed addiction treatment. Passionate about helping racial and ethnic minorities achieve wellness and recovery from substance use disorders, Dr. Jordan was fully drawn to community-based research. Her goal is to improve outcomes for patients from underrepresented racial and ethnic populations, by involving them in every step of the process, from research to clinical interaction. Dr. Jordan is working on an NIH-funded R01 project to provide a computer based cognitive behavioral therapy program known as (CBT4CBT) within the Black Church, an evidenced based therapeutic modality shown to be effective in decreasing substance use. She is also principal investigator of a faith-based recovery program based in 8 Black and Latinx churches throughout the state of CT.

She is elated and inspired to exist in an environment supportive of her vision to work with communities, integrating the cultural and religious aspects of people’s lives, while also addressing structural inequities that impede improved mental health and wellness. She is deeply grateful to be taking care of the most marginalized patients during this time, who are facing extreme challenges in obtaining addiction treatment due to COVID19. Dr. Jordan is the proud recipient of various clinical and research awards and was recently inducted into the Top 40 under 40 society, by her undergraduate alma mater, Hampton University, a historically Black institution.

Petros Levounis, MD, MA

Petros Levounis, MD, MAPetros Levounis, MD, MA, serves as professor and chair of the Department of Psychiatry and associate dean for professional development at Rutgers New Jersey Medical School. He is also the chief of service at University Hospital in Newark, New Jersey. Dr. Levounis came to Rutgers from Columbia University where he served as director of the Addiction Institute of New York from 2002 to 2013.

Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he researched the effects of social class on patient-physician relationships in Oxford, England, and received an MA degree in sociology from Stanford. In 1994, he moved to New York City to train in psychiatry at the New York State Psychiatric Institute of Columbia University. He graduated from Columbia earning the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University.

Dr. Levounis has written numerous articles, monographs, and book chapters; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by CBS, ABC, NBC, CNN, FOX, The Martha Stewart Radio Show, The New York Times, and The Washington Post, among others.

Dr. Levounis has served on the boards of the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine, and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association (APA). Dr. Levounis is a Betty Ford Scholar, a recipient of the Association of Gay and Lesbian Psychiatrists’ Distinguished Service Award and the ASAM Educator of the Year Award, and a distinguished fellow of the APA and ASAM. In 2017, he was elected as an honorary member of the World Psychiatric Association.

Dr. Levounis has published fourteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “Motivational Interviewing for Clinical Practice,” “The Behavioral Addictions,” “Becoming Mindful,” “LGBTQ Mental Health: The Spectrum of Gender and Sexuality,” “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition, and “Technological Addictions.” Dr. Levounis is currently working on the first textbook of Nature Therapy, which is going to be available in early 2022. His books have been translated into French, German, Hungarian, Japanese, Portuguese, and Spanish.

Dr. Levounis is married to actor Lukas Hassel and lives in New York City.

Carla Marienfeld, MD, DFAPA, FASAM

Carla Marienfeld, MD, DFAPA, FASAMCarla Marienfeld, MD, DFAPA, FASAM is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego who supports recovery in an evidence based, harm-reduction approach through therapy, motivational interviewing, and medication treatment. Her research involves analysis of electronic medical record data for individuals with substance use disorders. She has authored or co-authored over 35 peer reviewed articles, book chapters, practice guidelines, and invited commentaries, and she edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees about addiction psychiatry and effective interventions including buprenorphine treatment and motivational interviewing, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston. She is active in many professional organizations, including the American Society of Addiction Medicine, the American Association of Addiction Psychiatry, and the American Psychiatric Association.

Carla Marienfeld, MD, DFAPA, FASAM is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego. She edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has been highly involved in education of colleagues and trainees, and she is the fellowship director for the UCSD Addiction Psychiatry Fellowship. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale, and her medical degree with honors is from Baylor College of Medicine in Houston.

Sanchit Maruti, MD, MS

Sanchit Maruti, MD, MSDr. Sanchit Maruti, MD, MS, is the Medical Director of the UVM Medical Center (UVMMC), Addiction Treatment Program and the In-patient Psychiatry Service at UVMMC. He is also an Assistant Professor of Psychiatry at the Larner College of Medicine at the University of Vermont.

Dr. Maruti received his MD degree from the University of Vermont College of Medicine where he was awarded an Albert Schweitzer Fellowship.  He completed his residency training in Psychiatry at the UVMMC and served as Chief Resident during his final year.  He was recognized as the UVMMC Resident of Year and received the Arnold P. Gold Award for Humanism and Excellence in Clinical Teaching. He completed Fellowship training in Addiction Psychiatry at the Massachusetts General Hospital and Harvard Medical School.

Dr. Maruti’s clinical focus is on working with acutely ill patients and those with co-occurring disorders. His research interests are in the areas of risk assessment and quality improvement. He has worked with national experts on the revision of the national buprenorphine waiver course. He is the Course Director for the American Academy of Addiction Psychiatry (AAAP) annual Addictions and Their Treatment Course. Additionally, he serves on the Board of Directors of the AAAP.

Edward V. Nunes, MD

Edward V. Nunes, MDDr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Multiple PI of the Greater New York Node of the NIDA Clinical Trials Network (CTN), and Co-Director of the CHOSEN Center at Columbia University. He is a practicing psychiatrist Board Certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of opioid, cocaine and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression and other psychiatric disorders among patients with substance use disorders and the development of pharmacological and behavioral treatments for substance use disorders, as well as for his work in the CTN testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with the design, conduct and analysis of clinical trials of treatments for opioid use disorder, including technology-based interventions and extended-release injections and implants of buprenorphine and naltrexone.

John A. Renner, Jr., MD

John A. Renner, Jr., MDDr. Renner is Professor of Psychiatry, Boston University School of Medicine, and Associate Chief of Psychiatry for the VA Boston Healthcare System. He graduated from Yale University and Case University School of Medicine and completed his psychiatric residency at the Tufts- New England Medical Center. In 1969, Dr. Renner served as a psychiatrist with the US Navy in Vietnam, and since 1979 he has been working at the Boston VA in their outpatient addiction treatment program. In addition to his clinical activities at the VA, he is Associate Director of the Boston University Medical Center General Psychiatry Residency Program and Director of their Addiction Psychiatry Residency.

Dr. Renner has written and lectured extensively on the treatment of alcoholism and drug addiction. He is a member and former chair of the American Psychiatric Association Council on Addiction Psychiatry, former chair of the APA Council on Adult Psychiatry and former Chair of the APA Expert Advisory Panel on Addiction Psychiatry. In 2018, Dr. Renner co-edited the 2nd edition of the APA Handbook of Office-Based Buprenorphine Treatment for Opioid Use Disorder. He is Past-President of the Board of Directors of the American Academy of Addiction Psychiatry, and a member of the Data Safety Monitoring Board for the Clinical Trials Network of the National Institute on Drug Abuse, a member of the Clinical Advisory Committee of the Physician Health Service of the Massachusetts Medical Society, a Consultant to the Department of Psychiatry, Massachusetts General Hospital, and a member of the faculty of the Harvard Medical School Division on Addictions.

Richard K. Ries, MD

Richard K. Ries, MDDr. Ries is Professor of Psychiatry at the University of Washington School of Medicine, in Seattle, Washington. He is board certified in General Psychiatry and in Addiction Psychiatry by the American Board of Psychiatry and Neurology and certified in Addiction Medicine by the American Board of Addiction Medicine. Dr. Ries is Director of the Addictions Programs at Harborview Medical Center in downtown Seattle and Director of the Division of Addictions for the Department of Psychiatry. He was chosen to chair the first national consensus Treatment Improvement Protocol (TIP#9) and TIP #42 on assessment and treatment of persons with co-occurring addiction and mental disorders by the Center for Substance Abuse Treatment. Dr Ries was senior editor of the Key reference text ASAM’s Principles of Addiction Medicine editions 4 and 5. He is currently working on several NIDA, NIAAA, and DOD sponsored grants in the area of addictions treatment and addiction and suicide. His CV includes more than 150 published papers in peer reviewed journals.

Kevin A. Sevarino, MD, PhD

Kevin A. Sevarino, MD, PhDDr. Sevarino trained in psychiatry in the dual clinical/basic research tract at the Yale University School of Medicine. For six years thereafter, he was PI on NIH grants examining neurobiological mechanisms underlying cocaine dependence, and since then has transitioned to being a clinician-educator who remained active in clinical research as a member of the MIRECC VA Team in studies examining new treatments for substance use disorders. He was Medical Director of the Newington Mental Health Care Firm, Connecticut VA Healthcare System from Dec. 2004 through Aug. 2017. He is consulting psychiatrist to Gaylord Hospital, Wallingford, a position he previously held from 1999 - 2009. His particular expertise is in treatment of the dually-diagnosed and non-opiate pharmacological management of chronic pain. He is Associate Clinical Professor of Psychiatry, Yale University School of Medicine. He was subspecialty certified in Psychosomatic Medicine by the American Board of Psychiatry and Neurology from 2009 - 2019, in Addiction Medicine by the American Board of Addiction Medicine from 2010 - 2020, and currently in Addiction Medicine by the American Board of Preventative Medicine. Dr. Sevarino is President of the American Academy of Addiction Psychiatry (AAAP). He was Course Director for the AAAP Board Review Course in Addictions, which developed into the Addictions and Their Treatment Course, from 2007 - 2015. He currently co-directs AAAP’s Advanced Addiction Psychopharmacology course.

Laurence M. Westreich, MD

Laurence M. Westreich, MDLaurence M. Westreich, MD is a psychiatrist who specializes in the treatment patients diagnosed with Substance Use Disorders (SUDs), and those dually diagnosed with SUDs and mental disorders. After receiving a bachelor’s degree in English Literature from Northwestern University, he graduated from the University of Minnesota School of Medicine. Following an internship in Internal Medicine at the Hennepin County Medical Center in Minneapolis, Minnesota, Dr. Westreich completed a residency in Psychiatry at New York’s Beth Israel Medical Center and a two-year fellowship in addiction psychiatry at New York University/Bellevue Hospital. He is board – certified in general psychiatry, addiction psychiatry, and forensic psychiatry. Dr. Westreich is Associate Professor of Clinical Psychiatry in the Department of Psychiatry, New York University School of Medicine, and the author of Helping the Addict you Love (Simon and Schuster, 2007), and A Parent’s Guide to Teen Addiction (Skyhorse Publishing, 2017). In his professional practice, Dr. Westreich treats addicted and dually diagnosed individuals, and serves as a consultant in forensic matters, especially drug testing, child custody disputes, and disability. Dr. Westreich is Past President of the American Academy of Addiction Psychiatry and serves as Consultant on Behavioral Health and Addiction to the Commissioner of Major League Baseball.

Amy Yule, MD

Amy Yule, MDDr. Amy Yule is board certified in adult, child, and addiction psychiatry. She is the Director of Adolescent Addiction Psychiatry at Boston Medical Center and an Assistant Professor at the Boston University School of Medicine. Dr. Yule works with youth with substance use disorders and co-occurring psychiatric disorders as well as their family in a multidisciplinary outpatient clinic. She also has NIH funding to examine interventions to prevent substance use disorders in youth with psychiatric disorders. Lastly, Dr. Yule is the co-chair of the Women in Addiction Psychiatry Interest Group for the American Academy of Addiction Psychiatry.